30. Paediatric malignancies - The GEC-ESTRO Handbook of Brachytherapy

Paediatric malignancies

15

THE GEC ESTRO HANDBOOK OF BRACHYTHERAPY | Part II Clinical Practice Version 1 - 01/09/2023

Pädiatr 1995; 207 (4): 164-73. 59. Raney RB, Maurer HM, Anderson JR, Andrassy RJ, Donaldson SS, Qualman SJ, et al. The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols. Sarcoma. 2001;5:9-15. doi: 10.1080/13577140120048890. 60. Réguerre Y, Martelli H, Rey A, Rogers T, Gaze M, Ben Arush MW, et al. Local therapy is critical in localised pelvic rhabdomyosarcoma: experience of the International Society of Paediatric Oncology Malignant Mesenchymal Tumour (SIOP-MMT) committee. Eur J Cancer. 2012;48:2020-7. 61. Rodeberg DA, Anderson JR, Arndt CA, et al. Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: Combined results from the Children’s Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Paediatric Oncology Malignant Mesenchymal Tumours Committee. Int J Cancer 2011;128:1232-1239. 62. Romano E, Simon R, Minard-Colin V, et al. Analysis of Radiation Dose/Volume Effect Relationship for Anorectal Morbidity in Children Treated for Pelvic Malignancies. Int J Radiat Oncol Biol Phys. 2021;109:231-241. 63. Schoot RA, Saeed P, Freling NJ, et al. Local Resection and Brachytherapy for Primary Orbital Rhabdomyosarcoma: Outcome and Failure Pattern Analysis. Ophthalmic Plast Reconstr Surg. 2016;32(5):354-360. doi:10.1097/ IOP.0000000000000562 64. Schoot RA, Slater O, Ronckers CM, et al. Adverse events of local treatment in long-term head and neck rhabdomyosarcoma survivors after external beam radiotherapy or AMORE treatment. Eur J Cancer. 2015;51(11):1424-1434. doi:10.1016/j.ejca.2015.02.010 65. Schouwenburg PF, Kupperman D, Bakker FP, Blank LE, de Boer HB, Voute PA. New combined treatment of sur-gery, radiotherapy, and reconstruction in head and neckrhabdomyosarcoma in children: the AMORE protocol. Head Neck 1998;20:283–292 66. Sütterlin AL, Demmert M, Kovács G, Claviez A, Schulz C, Lauten M. Interventional radiotherapy (brachytherapy) achieves very good long-term quality of life in children and adolescents with soft-tissue sarcoma. Pediatr Blood Cancer. 2020 Oct;67(10):e28464. 67. Terlizzi M, Minard V, Haie-Meder C, et al. Implementation of Image-Guided Brachytherapy for Paediatric Vaginal Cancers: Feasibility and Early Clinical Results. Cancers (Basel). 2022;14(13):3247. Published 2022 Jul 1. doi:10.3390/ cancers14133247 68. Vaarwerk B, Hol MLF, Schoot RA, Breunis WB, de Win MML, Westerveld H, Fajardo RD, Saeed P, van den Brekel MW, Pieters BR, Strackee SD, Smeele LE, Merks JHM. AMORE treatment as salvage treatment in children and young adults with relapsed head-neck rhabdomyosarcoma. Radiother Oncol. 2019 Feb;131:21-26. 69. Williamson D, Missiaglia E, de Reyniès A, Pierron G, Thuille B, Palenzuela G, Thway K, Orbach D, Laé M, Fréneaux P, Pritchard-Jones K, Oberlin O, Shipley J, Delattre O. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol. 2010 May 1;28(13):2151-8.

38. Limkin EJ, Guérin F, Espenel S, Terlizzi M, Martelli H, Haie-Meder C, Minard V, Chargari C. Use of an intravaginal spacer in young girls treated with brachytherapy for bladder neck rhabdomyosarcoma: Dosimetric impact for organs at risk sparing and acute tolerance. Cancer Radiother. 2021 Oct 25: S1278-3218(21)00255-9. 39. Lobo S, Gaze MN, Slater O, Hoskin P, Sands G, Sullivan T, Cho A, Eminowicz G, Smeulders N. Bladder function after conservative surgery and high-dose rate brachytherapy for bladder-prostate rhabdomyosarcoma. Pediatr Blood Cancer. 2022 Jan 19:e29574. 40. Magné N, Chargari C, Levy A, et al. Clear cell adenocarcinoma of the female genital tract: long-term outcome and fertility aspects after brachytherapy aimed at a conservative treatment. Int J Gynecol Cancer. 2012;22:1378-82. 41. Magné N, Chargari C, SanFilippo N, Messai T, Gerbaulet A, Haie-Meder C. Technical aspects and perspectives of the vaginal mold applicator for brachytherapy of gynecologic malignancies. Brachytherapy. 2010 Jul-Sep;9(3):274-7. 42. Magné N, Haie-Meder C. Brachytherapy for genital-tract rhabdomyosarcomas in girls: technical aspects, reports, and perspectives. Lancet Oncol. 2007;8:725-9. 43. Magné N, Oberlin O, Martelli H, Gerbaulet A, Chassagne D, Haie-Meder C. Vulval and vaginal rhabdomyosarcoma in children: update and reapprail of Institut Gustave Roussy brachytherapy experience. Int J Radiat Oncol Biol Phys. 2008;72:878-83. 44. Malempati S, Rodeberg DA, Donaldson SS, Lyden ER, Anderson JR, Hawkins DS, Arndt CA. Rhabdomyosarcoma in infants younger than 1 year: a report from the Children's Oncology Group. Cancer. 2011 Aug 1;117(15):3493-501 45. Martelli H, Borrego P, Guérin F, Boubnova J, Minard-Colin V, Dumas I, Chargari C, Haie-Meder C. Quality of life and functional outcome of male patients with bladder-prostate rhabdomyosarcoma treated with conservative surgery and brachytherapy during childhood. Brachytherapy. 2016 May-Jun;15(3):306-311. 46. Martelli H, Haie-Meder C, Branchereau S, Franchi-Abella S, Ghigna MR, Dumas I, Bouvet N, Oberlin O. Conservative surgery plus brachytherapy treatment for boys with prostate and/or bladder neck rhabdomyosarcoma: a single team experience. J Pediatr Surg. 2009 Jan;44(1):190-6. 47. Martelli H, Oberlin O, Rey A, et al. Conservative treatment for girls with non metastatic rhabdomyosarcoma of the genital tract: a report from the Study Committee of the International Society of Paediatric Oncology. J Clin Oncol 1999; 17 (7): 2117-22. 48. Merchant TE, Parsh N, del Valle PL, et al. Brachytherapy for paediatric soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 2000; 46 (2): 427-32. 49. Merchant TE, Zelefsky MJ, Sheldon JM, et al. High-dose rate intraoperative radiation therapy for paediatric solid tumours. Med Pediatr Oncol 1998 ; 30: 34-3. 50. Mertens AC, Liu Q, Neglia JP et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2008;100:1368–1379 51. Miller KD, Fidler-Benaoudia M, Keegan TH, Hipp HS, Jemal A, Siegel RL. Cancer statistics for adolescents and young adults, 2020. CA Cancer J Clin. 2020;70:443-459. 52. Minard-Colin V, Walterhouse D, Bisogno G, et al. Localized vaginal/uterine rhabdomyosarcoma-results of a pooled analysis from four international cooperative groups. Pediatr Blood Cancer. 2018 Sep;65(9):e27096. 53. Nag S, Olson T, Ruymann F, et al. High-dose-rate brachytherapy in childhood sarcomas: a local control strategy preserving bone growth and function. Med Ped Oncol 1995; 25: 463-9. 54. Nag S, Tippin D, Ruymann FB. Intraoperative high-dose-rate brachytherapy for the treatment of paediatric tumours: The Ohio State University experience. Int J Radiat Oncol Biol Phys 2001;51:729-735. 55. Palmer JD, Hall MD, Mahajan A, Paulino AC, Wolden S, Constine LS. Radiotherapy and Late Effects. Pediatr Clin North Am. 2020 Dec;67(6):1051-1067. 56. Papillon J, Montbarbon JF, Gerard JP, Chassard JL, Ardiet JM. Interstitial curietherapy in the conservative treatment of anal and rectal cancers. Int J Radiat Oncol Biol Phys. 1989;17(6):1161-1169. doi:10.1016/0360-3016(89)90521-x 57. Parham DM, Barr FG. Classification of rhabdomyosarcoma and its molecular basis. Adv Anat Pathol. 2013 Nov;20(6):387-97 58. Pötter R, Knocke TH, Kovacs G, et al. Brachytherapy in the combined modality treatment of paediatric malignancies. Principles and preliminary experience with treatment of soft tissue sarcoma (recurrence) and Ewing’s sarcoma. Klin